Download Curriculum Vitae

Dr. Gong obtained his Ph.D. degree at 2013 in Wuhan University, China. His Ph.D. research focused on some molecules extracted from traditional Chinese medicine and their anti-tumor activities, alone or in combination with approved anticancer drugs, on various cancer types including liver cancer, breast cancer, gliomas, and leukemia.

In 2014, Dr. Gong joined the Department of  Neurology at University of Texas Southwestern Medical Center, as a postdoctoral fellow, and is now an Instructor in the same department. His current studies are aimed to interpret and try to overcome drug resistance mechanisms of EGFR inhibitors on lung cancer and gliomas, which were associated with EGFR signal transduction, inflammatory and antiviral signaling pathways interacting with oncogenic signaling networks. His works were based on cell cultures, animal models, patient data, and open cancer databases. These studies are clinically translatable and will be tested in clinical trials at University of Texas Southwestern Medical Center quite soon.

Dr. Gong was keeping interests in cancer biology and therapy, especially in drug resistance, and combination therapy. He has published over 15 peer-review articles and reviews, 7 of which are first/co-first author.  He is wishing to translate his laboratory findings into realworld applications and benefit cancer patients.

Research Interest

  • Clinically applying the combination therapy with a dramatic preclinical effect that found at UT Southwestern Medical Center to benefit more cancer patients.
  • Mining big data to discover new druggable targets in cancer treatment and drug resistance.
  • Validating these targets from the molecular/cellular levels to animal models and clinical trials.


Featured Publications LegendFeatured Publications

Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.
Guo G, Gong K, Puliyapaddamba VT, Panchani N, Pan E, Mukherjee B, Damanwalla Z, Bharia S, Hatanpaa KJ, Gerber DE, Mickey BE, Patel TR, Sarkaria JN, Zhao D, Burma S, Habib AA, Neuro-oncology 2019 Jul
C/EBPß regulates delta-secretase expression and mediates pathogenesis in mouse models of Alzheimer's disease.
Wang ZH, Gong K, Liu X, Zhang Z, Sun X, Wei ZZ, Yu SP, Manfredsson FP, Sandoval IM, Johnson PF, Jia J, Wang JZ, Ye K, Nat Commun 2018 05 9 1 1784
A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma.
Guo G, Gong K, Ali S, Ali N, Shallwani S, Hatanpaa KJ, Pan E, Mickey B, Burma S, Wang DH, Kesari S, Sarkaria JN, Zhao D, Habib AA, Nat. Neurosci. 2017 Aug 20 8 1074-1084
Analysis of Constitutive EGFR Signaling Regulating IRF3 Transcriptional Activity in Cancer Cells.
Guo G, Gong K, Habib AA, Methods Mol. Biol. 2017 1652 183-189
Ligand-Independent EGFR Signaling.
Guo G, Gong K, Wohlfeld B, Hatanpaa KJ, Zhao D, Habib AA, Cancer Res. 2015 Sep 75 17 3436-41
Extracellular signal-regulated kinase, receptor interacting protein, and reactive oxygen species regulate shikonin-induced autophagy in human hepatocellular carcinoma.
Gong K, Zhang Z, Chen Y, Shu HB, Li W, Eur. J. Pharmacol. 2014 Sep 738 142-52
Sj7170, a unique dual-function peptide with a specific a-chymotrypsin inhibitory activity and a potent tumor-activating effect from scorpion venom.
Song Y, Gong K, Yan H, Hong W, Wang L, Wu Y, Li W, Li W, Cao Z, J. Biol. Chem. 2014 Apr 289 17 11667-80
Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.
Wan J, Liu T, Mei L, Li J, Gong K, Yu C, Li W, Br. J. Cancer 2013 Jul 109 2 342-50